Imaging Quality and Potential Clinical Relevance of Phase Contrast Mammography In-vivo: a Single-center, Prospective Study
NCT ID: NCT06489665
Last Updated: 2025-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
350 participants
OBSERVATIONAL
2024-10-17
2030-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility of Comparing Microwave Images and Mammograms in Patients Recalled for Follow-up Breast Imaging
NCT07273565
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study
NCT01433640
MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk
NCT01649661
" Role of Diffusion Weighted Image in the Diagnosis and Follow up of Breast Cancer"
NCT06494865
Comparison of the Philips MicroDose Tomosynthesis System to 2D Digital Mammography
NCT02615509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective(s):
Phase 0: Imaging of mastectomy and breast biopsy samples to validate the image quality and radiation dose. Phase 1: Determination of accurate radiation dose in vivo; dose exposure should remain within the range specified in the investigational brochure. Evaluation of cohort size for phase 2. Phase 2: Assessment of the diagnostic performance of phase contrast mammography compared to conventional digital mammography.
Ouctomes: Sensitivity and specificity of phase contrast mammography compared to conventional digital mammography.
Measurements and procedures:
Phase 0: Phase contrast mammography of the mastectomy, tumorectomy or breast biopsy samples is performed after breast surgery in addition to the standard clinical procedures Phase 1: Phase contrast mammography is performed before the operation in case of known breast carcinoma in addition to the standard clinical procedures Phase 2: Phase contrast mammography is performed directly in the clinical routine. The result is compared with the result of the conventional digital mammography and the ultrasound examination.
Number of Participants with Rationale:
Phase 0: expected to be 30 Phase 1: expected to be 20 Phase 2: expected to be 300 (correct number will be defined according to Phase 1)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mammography finding
Describes the mammography finding in patients prior breast surgery
Experimental Intervention
Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
Bellona
Describes the finding in the breast tissue samples
Experimental Intervention
Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental Intervention
Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mastectomy, tumorectomy or biopsy planned
* Informed consent of the patient
* \>18 years
* BI-RADS 5 (highly suggestive of malignancy at ultrasound or mammography) or 6 (known biopsy proven malignancy);
* Scheduled for mastectomy or breast conserving surgery with radiotherapy.
* Informed consent of the patient
* \>40 years
* undergoing mammography for screening or diagnostic purpose.
* Informed consent of the patient
Exclusion Criteria
* Inability to understand the study procedure due to cognitive or linguistic deficits.
* Pregnancy
* Breast-feeding.
* Re-staging after neoadjuvant chemotherapy. Patients who participated in prior research projects with ionizing radiation in the past 12 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland
OTHER
GratXray AG
UNKNOWN
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Frau, Prof
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, DIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich - Diagnostic Radiology
Zurich, Canton of Zurich, Switzerland
University of Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-00200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.